Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain
- PMID: 23534988
- DOI: 10.1586/erp.13.18
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain
Abstract
Aim: The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel) in the treatment of patients with previously treated metastatic breast cancer in Spain.
Materials & methods: Efficacy data were obtained from the CA012 trial (nab-paclitaxel administered every 3 weeks [q3w] and sb-paclitaxel q3w) and indirect comparison (sb-paclitaxel administered weekly), and were modeled to a time horizon of 5 years using a Markov model. The analysis was performed from the National Health Service perspective. Use of resources and key assumptions of the model were validated by a panel of 22 local oncologists.
Results: Compared with sb-paclitaxel q3w, nab-paclitaxel q3w was cost effective, with a cost per life year gained of €11,088 and a cost per quality-adjusted life year of €17,808. Compared with sb-paclitaxel administered weekly, it showed savings of €711 per patient.
Conclusion: The COSTABRAX study showed that nab-paclitaxel q3w is a cost-effective alternative compared with sb-paclitaxel q3w and a cost-saving alternative to sb-paclitaxel administered weekly in Spain.
Similar articles
-
nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.Breast Cancer Res Treat. 2010 Feb;119(3):717-24. doi: 10.1007/s10549-009-0424-z. Epub 2009 Jun 3. Breast Cancer Res Treat. 2010. PMID: 19495958 Clinical Trial.
-
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.J Oncol Pharm Pract. 2009 Jun;15(2):67-78. doi: 10.1177/1078155208098584. Epub 2008 Nov 26. J Oncol Pharm Pract. 2009. PMID: 19036903
-
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.Breast. 2011 Oct;20(5):468-74. doi: 10.1016/j.breast.2011.07.005. Epub 2011 Aug 16. Breast. 2011. PMID: 21843943 Clinical Trial.
-
Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Crit Rev Oncol Hematol. 2014. PMID: 24071503 Review.
-
Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.Expert Opin Pharmacother. 2010 Jun;11(8):1413-32. doi: 10.1517/14656561003796562. Expert Opin Pharmacother. 2010. PMID: 20446855 Review.
Cited by
-
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.Clinicoecon Outcomes Res. 2018 Nov 14;10:773-790. doi: 10.2147/CEOR.S178934. eCollection 2018. Clinicoecon Outcomes Res. 2018. PMID: 30532569 Free PMC article.
-
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.Curr Oncol. 2023 Aug 30;30(9):7984-8004. doi: 10.3390/curroncol30090580. Curr Oncol. 2023. PMID: 37754495 Free PMC article.
-
Albumin Nanovectors in Cancer Therapy and Imaging.Biomolecules. 2019 Jun 5;9(6):218. doi: 10.3390/biom9060218. Biomolecules. 2019. PMID: 31195727 Free PMC article. Review.
-
nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings.Exp Hematol Oncol. 2017 Mar 22;6:7. doi: 10.1186/s40164-017-0066-5. eCollection 2017. Exp Hematol Oncol. 2017. PMID: 28344858 Free PMC article. Review.
-
Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs.Pharmaceutics. 2022 Aug 17;14(8):1722. doi: 10.3390/pharmaceutics14081722. Pharmaceutics. 2022. PMID: 36015347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
